These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 29125702

  • 21. A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers.
    Hosseini A, McLachlan AJ, Lickliter JD.
    Br J Clin Pharmacol; 2021 Apr; 87(4):2070-2077. PubMed ID: 33075170
    [Abstract] [Full Text] [Related]

  • 22. Model-Based Analysis of Cannabidiol Dose-Exposure Relationship and Bioavailability.
    Lim SY, Sharan S, Woo S.
    Pharmacotherapy; 2020 Apr; 40(4):291-300. PubMed ID: 32058609
    [Abstract] [Full Text] [Related]

  • 23. Cannabidiol Oil Ingested as Sublingual Drops or Within Gelatin Capsules Shows Similar Pharmacokinetic Profiles in Healthy Males.
    Johnson DA, Funnell MP, Heaney LM, Cable TG, Wheeler PC, Bailey SJ, Clifford T, James LJ.
    Cannabis Cannabinoid Res; 2024 Oct; 9(5):e1423-e1432. PubMed ID: 37733294
    [Abstract] [Full Text] [Related]

  • 24. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
    Molnar A, Fu S, Lewis J, Allsop DJ, Copeland J.
    Forensic Sci Int; 2014 May; 238():113-9. PubMed ID: 24699310
    [Abstract] [Full Text] [Related]

  • 25. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.
    Patti F.
    Neurodegener Dis Manag; 2019 Apr; 9(2s):3-7. PubMed ID: 30657027
    [Abstract] [Full Text] [Related]

  • 26. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy.
    Birnbaum AK, Karanam A, Marino SE, Barkley CM, Remmel RP, Roslawski M, Gramling-Aden M, Leppik IE.
    Epilepsia; 2019 Aug; 60(8):1586-1592. PubMed ID: 31247132
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetics of Cannabidiol: A Systematic Review and Meta-Regression Analysis.
    Moazen-Zadeh E, Chisholm A, Bachi K, Hurd YL.
    Cannabis Cannabinoid Res; 2024 Aug; 9(4):939-966. PubMed ID: 37643301
    [Abstract] [Full Text] [Related]

  • 28. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT.
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [Abstract] [Full Text] [Related]

  • 29. Evaluation of amorphous and lipid-based formulation strategies to increase the in vivo cannabidiol bioavailability in piglets.
    Koch N, Jennotte O, Bourcy Q, Lechanteur A, Deville M, Charlier C, Chiap P, Cardot JM, Evrard B.
    Int J Pharm; 2024 May 25; 657():124173. PubMed ID: 38685441
    [Abstract] [Full Text] [Related]

  • 30. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P, Trojano M.
    Eur Neurol; 2016 May 25; 76(5-6):216-226. PubMed ID: 27732980
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetics of Cannabidiol in Sprague-Dawley Rats After Oral and Pulmonary Administration.
    Schwotzer D, Kulpa J, Trexler K, Dye W, Jantzi J, Irshad H, Ware MA, Bonn-Miller M, McDonald J, Lefever T.
    Cannabis Cannabinoid Res; 2023 Apr 25; 8(2):360-373. PubMed ID: 36301522
    [Abstract] [Full Text] [Related]

  • 32. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.
    Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, Allen P, Seal M, Langohr K, Farré M, Zuardi AW, McGuire PK.
    Curr Pharm Des; 2012 Apr 25; 18(32):4966-79. PubMed ID: 22716148
    [Abstract] [Full Text] [Related]

  • 33. Enhanced oral bioavailability and in vitro evaluation of cannabidiol camel milk-derived exosome formulation in resistant MDA-MB-231 and MDA-MB-468 breast cancer cells.
    Aare M, Bagde A, Nathani A, Rishi AK, Singh M.
    Int J Pharm; 2024 Sep 30; 663():124375. PubMed ID: 38914353
    [Abstract] [Full Text] [Related]

  • 34. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans.
    Manini AF, Yiannoulos G, Bergamaschi MM, Hernandez S, Olmedo R, Barnes AJ, Winkel G, Sinha R, Jutras-Aswad D, Huestis MA, Hurd YL.
    J Addict Med; 2015 Sep 30; 9(3):204-10. PubMed ID: 25748562
    [Abstract] [Full Text] [Related]

  • 35. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C, Bujanover S, Kareht S, Rapoport AM.
    Headache; 2015 Feb 30; 55(2):265-75. PubMed ID: 25546369
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Precipitation complexation method produces cannabidiol/beta-cyclodextrin inclusion complex suitable for sublingual administration of cannabidiol.
    Mannila J, Järvinen T, Järvinen K, Jarho P.
    J Pharm Sci; 2007 Feb 30; 96(2):312-9. PubMed ID: 17051591
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.